Upgrades According to Northland Capital Markets, the prior rating for Clearfield Inc (NASDAQ:CLFD) was changed from Market Perform to Outperform. For the second quarter, Clearfield had an EPS of $0.27, compared to year-ago quarter EPS of $0.05. The current stock performance of Clearfield shows a 52-week-high of $38.75 and a 52-week-low of $11.46. Moreover, at the end of the last trading period, the closing price was at $29.96. According to Raymond James, the prior rating for Cimarex Energy Co (NYSE:XEC) was changed from Outperform to Strong Buy. For the fourth quarter, Cimarex Energy had an EPS of $0.89, compared to year-ago quarter EPS of $1.18. At the moment, the stock has a 52-week-high of $69.35 and a 52-week-low of $20.05. Cimarex Energy closed at $60.80 at the end of the last trading period. For Continental Resources Inc (NYSE:CLR), Raymond James upgraded the previous rating of Market Perform to Outperform. In the fourth quarter, Continental Resources showed an EPS of $0.23, compared to $0.55 from the year-ago quarter. At the moment, the stock has a 52-week-high of $32.39 and a 52-week-low of $11.09. Continental Resources closed at $25.31 at the end of the last trading period. For Ovintiv Inc (NYSE:OVV), Wolfe Research upgraded the previous rating of Peer Perform to Outperform. In the fourth quarter, Ovintiv showed an EPS of $0.70, compared to $0.81 from the year-ago quarter. The current stock performance of Ovintiv shows a 52-week-high of $28.69 and a 52-week-low of $4.04. Moreover, at the end of the last trading period, the closing price was at $21.97. For Marathon Oil Corp (NYSE:MRO), Wolfe Research upgraded the previous rating of Peer Perform to Outperform. Marathon Oil earned $0.12 in the fourth quarter, compared to $0.07 in the year-ago quarter. The stock has a 52-week-high of $13.29 and a 52-week-low of $3.73. At the end of the last trading period, Marathon Oil closed at $10.33. According to WBB Securities, the prior rating for Paratek Pharmaceuticals Inc (NASDAQ:PRTK) was changed from Speculative Buy to Buy. For the fourth quarter, Paratek Pharmaceuticals had an EPS of $0.49, compared to year-ago quarter

Share.

Comments are closed.